-
Akers Biosciences Responds to Erroneous Earnings Call Press Release
Akers Biosciences Responds to Erroneous Earnings Call Press Release
Share
NEW YORK--(BUSINESS WIRE)--Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learning more about the cause of this error.
Contacts
Investor Relations: Hayden IR
Brett Mass, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
More News From Akers Biosciences, Inc.
MyMD Pharmaceuticals Set to Join Russell Microcap® Index
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effective after the US market opens on June 28, according to a preliminary list of additions posted June 4. Membership in the Russell Microcap® Index, which remains in place for one ye...
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company’s Scientific Advisory Board. “I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms,” stated David Rini. David Rini is a Professor at the...
MyMD Pharmaceuticals Schedules Business Update Conference Call
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced it will host a conference call at 4:15 p.m. Eastern time on Monday, May 17th to provide an update on its clinical and drug development plan. To participate in the briefing session, please click on the link below to register. Questions can be submitted in advance via the contact inform...